ISSN: 1859 - 2872
Correlation between serum interleukin-6 (IL-6) concentration and clinical characterisics in patients with ST elevation myocardial infarction (STEMI)
Main Article Content
Keywords
Abstract
Objective: To investigate the correlation between serum interleukin-6 concentration and some clinical characteristics in patients with STEMI. Subject and method: This is a cross-sectional descriptive study on 60 STEMI patients who was admitted to 108 Military Central Hospital from Octorber 2023 to April 2024. Result: The median of IL-6 concentration was 20.2pg/mL (lower quartile: 9.2pg/mL, upper quartile: 35.6pg/mL), significantly higher than the reference value, p value<0.001. IL-6 concentration in the group with Killip II-IV heart failure was 61.1 (30.9; 79.3) pg/mL, higher than in the Killip I group, level of 10.9 (8.3; 23.2) pg/mL, p value<0.001. There was a significant positive correlation between serum IL-6 concentration and the time interval from onset to admission (r = 0.501, p value <0.001) and with TIMI score (r = 0.694, p value<0.001). Conclusion: IL-6 levels are elevated in patients with acute myocardial infarction. There is a positive correlation between plasma IL-6 concentration and the time interval of myocardial infarction from onset to hospitalization, and with the TIMI-risk score.
Article Details
References
2. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9): 1135-1143.
3. Huang M, Yang D, Xiang M, et al (2015) Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction. Heart failure reviews 20: 25-38.
4. Tiller C, Reindl M, Holzknecht M et al (2022) Association of plasma interleukin-6 with infarct size, reperfusion injury, and adverse remodelling after ST-elevation myocardial infarction. European Heart Journal Acute Cardiovascular Care 11(2): 113-123.
5. Kristensen SD and Aboyans V (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European heart journal 39: 119-177.
6. Jones SA, Takeuchi T, Aletaha D et al (2018) Interleukin 6: The biology behind the therapy. Considerations in Medicine 2(1): 2-6.
7. Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102(17): 2031-2037.
8. Miyao Y, Yasue H, Ogawa H et al (1993) Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. American heart journal 126(6): 1299-1304.
9. Pudil R, Tichý M, Andrýs C et al (2010) Plasma interleukin-6 level is associated with NT-proBNP level and predicts short-and long-term mortality in patients with acute heart failure. Acta Medica (Hradec Kralove) 53(4): 225-228.
10. Lee KW, Lip GY, Tayebjee M et al (2005) Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 105(2): 526-532.